Shares of Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) experienced a sharp 5.66% decline in after-hours trading on Tuesday, reversing course from its recent rally. The plunge came shortly after the company announced the termination of its At-The-Market (ATM) Prospectus for common stock dated January 6, 2025.

The termination of the ATM Prospectus, a tool that allows companies to raise capital by selling newly issued shares directly into the market, may have sparked concerns among investors about the company's future financing strategies. This move could potentially limit Olema's flexibility in raising funds, which is crucial for biotechnology companies investing heavily in research and development.

The after-hours drop is particularly notable given Olema's recent strong performance. Earlier in the day, the stock had surged by over 140% following positive news in the breast cancer treatment space. Roche Holdings AG's encouraging phase 3 results for its SERD (Selective Estrogen Receptor Degrader) treatment had boosted investor optimism for Olema, which is developing a similar drug.

Despite the current setback, some analysts remain bullish on Olema's prospects. H.C. Wainwright had raised its price target for the company from $28 to $36 earlier in the day, maintaining a Buy rating. However, the sudden shift in investor sentiment highlights the volatile nature of biotech stocks, especially in reaction to corporate financial decisions and market dynamics.